Cargando…

Antiviral Treatments

Most viral respiratory tract infections are caused by classic respiratory viruses, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza, rhinovirus, and adenovirus, whereas other viruses, such as herpes simplex, cytomegalovirus, and measles virus, can opportunistica...

Descripción completa

Detalles Bibliográficos
Autor principal: Ison, Michael G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131036/
https://www.ncbi.nlm.nih.gov/pubmed/28159156
http://dx.doi.org/10.1016/j.ccm.2016.11.008
_version_ 1783517146409598976
author Ison, Michael G.
author_facet Ison, Michael G.
author_sort Ison, Michael G.
collection PubMed
description Most viral respiratory tract infections are caused by classic respiratory viruses, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza, rhinovirus, and adenovirus, whereas other viruses, such as herpes simplex, cytomegalovirus, and measles virus, can opportunistically affect the respiratory tract. The M2 inhibitors, amantadine and rimantadine, were historically effective for the prevention and treatment of influenza A but all circulating strains are currently resistant to these drugs. Neuraminidase inhibitors are the sole approved class of antivirals to treat influenza. Ribavirin, especially when combined with intravenous antibody, reduces morbidity and mortality among immunosuppressed patients.
format Online
Article
Text
id pubmed-7131036
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71310362020-04-08 Antiviral Treatments Ison, Michael G. Clin Chest Med Article Most viral respiratory tract infections are caused by classic respiratory viruses, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza, rhinovirus, and adenovirus, whereas other viruses, such as herpes simplex, cytomegalovirus, and measles virus, can opportunistically affect the respiratory tract. The M2 inhibitors, amantadine and rimantadine, were historically effective for the prevention and treatment of influenza A but all circulating strains are currently resistant to these drugs. Neuraminidase inhibitors are the sole approved class of antivirals to treat influenza. Ribavirin, especially when combined with intravenous antibody, reduces morbidity and mortality among immunosuppressed patients. Elsevier Inc. 2017-03 2016-12-13 /pmc/articles/PMC7131036/ /pubmed/28159156 http://dx.doi.org/10.1016/j.ccm.2016.11.008 Text en © 2016 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Ison, Michael G.
Antiviral Treatments
title Antiviral Treatments
title_full Antiviral Treatments
title_fullStr Antiviral Treatments
title_full_unstemmed Antiviral Treatments
title_short Antiviral Treatments
title_sort antiviral treatments
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131036/
https://www.ncbi.nlm.nih.gov/pubmed/28159156
http://dx.doi.org/10.1016/j.ccm.2016.11.008
work_keys_str_mv AT isonmichaelg antiviraltreatments